Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells
© The Author(s). 2017
Received: 11 September 2015
Accepted: 15 February 2017
Published: 20 March 2017
About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss.
Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance.
We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds.
These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.
KeywordsHypoxia Estrogen receptor HIF HIF-1α HIF-1 alpha Endocrine therapy Breast cancer Tamoxifen Aromatase inhibitor Drug resistance Endocrine therapy resistance
Breast tumors are classified into subtypes based on molecular and pathological characteristics that impart prognostic value or determine therapeutic treatment plans. The most common and clinically relevant feature is expression of the estrogen receptor alpha (ER-α; ESR1) transcription factor, which occurs in 70–80% of all breast tumors. ER-α is activated by the endogenous hormone 17-beta-estradiol (estrogen), to bind estrogen-responsive elements (ERE) in DNA and induce gene transcription (reviewed in [1, 2]). ER-α can also function as a non-DNA-binding element of other transcription complexes; and cytosolic, non-genomic functions are ascribed to specific ER-α splice variants.
Estrogen responsive genes include those required for survival and proliferation, and most ER-α -positive breast tumors are dependent on estrogen for growth. As such, several targeted therapies have been developed that either compete for estrogen binding (for example tamoxifen), or inhibit the body’s ability to produce estrogen (for example aromatase inhibitors). Most ER-α positive tumors initially respond well to these therapeutics, and ER-α expression generally imparts a better 5 year prognosis. However around 30% of ER-α positive tumors are intrinsically resistant to endocrine therapies and 30–40% of those that initially responded will become therapy resistant (reviewed in [1, 2]). Of these, about 20% will lose ER-α expression. Patients with endocrine-resistant tumors account for nearly 11,000 annual US breast cancer deaths.
Heterogeneity of ER-α positive tumors influences therapeutic responses
As a class, ER-α positive tumors are heterogeneous in the expression of hundreds of other molecules that may influence proliferation and survival. For example, some ER-α positive tumors express activated oncogenes such as the HER2 receptor tyrosine kinase, or a mutant, activated phosphoinositide-3-kinase alpha catalytic subunit (PI3KCA; [3–5]). Other ER-α positive tumors may have inactivated tumor suppressors such as tumor protein TP53) and/or retinoblastoma (Rb). Differences may be so profound that ER-α positive tumors are found in both the luminal A and luminal B molecular subsets of breast tumors. As expected from this heterogeneity, ER-α positive tumors differ in drug responses and clinical outcomes [6, 7].
Individual ER-α positive breast tumors also exhibit significant intra-tumor heterogeneity. Tumors are considered ER-α positive by clinical histopathological standards if as few as 1% of cells stain for ER-α expression . The presence of accompanying ER-α negative cells has been attributed to factors including genomic instability, epigenetic regulation, poorly-defined micro-environmental conditions, and the ongoing growth and differentiation of tumor cells from primitive, stem-cell like progenitors within the tumor mass . As the use of specifically-targeted therapeutics increases, intra-tumor heterogeneity becomes an increasingly important factor in treatment efficacy . The widespread use of hormone targeted therapeutics and prevalence of resistance, makes understanding the intra- and inter-tumor heterogeneity of ER-α positive tumor responses of paramount clinical importance. Thus, experimental analysis of only one or a few ER-α positive cell lines in preclinical studies cannot accurately reveal the diversity of potential responses among this class of tumors, nor predict the prevalence of various therapeutic responses.
HIF-1α is a key regulator of adaptation to hypoxic conditions
Conditions of low oxygen (i.e. hypoxia) are hallmarks of solid tumors, and cells undergo profound alterations to survive this environment (reviewed in ). Hypoxia promotes the growth of tumors that have reduced apoptotic abilities  increased metastatic potential  and increased genomic instability [14–16]. Hypoxia is a poor-prognosis factor for breast cancer in terms of tumor recurrence, tumor aggressiveness, disease-free survival and overall survival [17, 18]. Hypoxic conditions occur in poorly vascularized regions of rapidly growing tumors, areas located between 70 and 100 μm from blood vessels . Highly transformed breast cancer cells orchestrate a varety of complex responses to survive hypoxic conditions, allowing, for example, uninterrupted protein synthesis via constitutively activated mechanistic target of rapamycin (mTOR) signaling . In contrast, non-transformed breast derived cell lines respond to hypoxia (1% O2) by rapid inhibition of protein synthesis (reviewed in ).
Many features of hypoxic adaptation rely on activation of the hypoxia inducible factor (HIF) family of transcription factors. HIF functions as a heterodimer composed of an α-subunit (HIF-1α, HIF-2α or HIF-3α) and a β-subunit (HIF-1β). HIF-1α, and HIF-2α are the main transcription factors involved in oxygen level sensing and cell response (reviewed in [11, 16]) while HIF-1β (ARNT) is constitutively expressed in the nucleus independent of oxygen levels. Under normoxic conditions HIF-1α is hydroxylated on proline 402 and proline 564 by a family of prolyl-4-hydroxylases (PHDs;[22, 23]). HIF-1α hydroxylation allows recognition by the von Hippel-Lindau (VHL) tumor suppressor, which targets HIF-1α to the proteasome for degradation. Under hypoxic conditions HIF-1α degradation is impaired, allowing nuclear translocation and hetero-dimerization with HIF-1β on hypoxic-response elements (HRE). HIF-directed transcription induces genes involved in angiogenesis, glycosylation, tissue remodeling, metabolism, and cell proliferation [24–26]. HIF-1α is an independent predictor of poor response to chemo-endocrine therapy, and is negatively associated with disease-free survival in ER-α positive but not ER-α negative patients .
Conflicting observations regarding hypoxic alterations in ESR1 transcription, ER-α protein stability, and ER-α transcriptional activity appear in the literature [28–31]. Some of these reports use cell culture with low environmental oxygen, but more often they use treatment with chemicals that can stabilize HIF-1α to the mimic hypoxic environment. With regard to breast cancer, these studies also primarily rely on the singular cell line MCF7, or a cell line of unknown lineage and genomic content, ZR-75. While this literature generally suggests that hypoxia promotes decreased ER-α expression, it does not present a coherent mechanistic picture that could guide improvements in hormonal therapeutics.
ER-α protein levels are reduced in hypoxic environments
In the current study, we analyze the effect of hypoxia and HIF expression on ER-α using a panel of ten independently-derived ER-α positive cell lines. This panel has been previously characterized by comparative genomic hybridization, mRNA expression profiling, total genome sequencing, various high throughput analyses of protein expression and activation status, and comprehensive drug panel responses (for example, see [7, 32, 33]). Combined, these cell lines capture a significant amount of the diverse genetic backgrounds and accompanying mutations commonly present in ER-α positive tumors. Cell lines in our study such as BT474 and MDA-MB-361 co-express and constitutively activate the HER2 receptor tyrosine kinase; five of these cell lines bear activating mutations in the phosphatidylinositol-4, 5-bisphosphate 3-kinase subunit PIKC3A; five have mutated TP53 genes, and lines such as HCC1428 and MDA-MB-175 maintain wildtype alleles of all of these genes (Additional file 1; [3–5, 33]). Despite this genomic and drug response diversity we find that hypoxia commonly functions through HIF-1α to reduce ER-α protein levels, impede ER-α directed transcription, and inhibit estrogen-dependent cell proliferation. The latter occurs even in cells that co-express receptor tyrosine kinases such as HER2, which are known to drive breast tumor proliferation in other settings.
LY2, MCF7, CAMA-1, MDA-MB-175, MDA-MB-361, MDA-MB-231 and MDA-MB-435 cell lines were cultured in DMEM. BT474, T47D, ZR75B, MPE600, HCC1428 cell lines were cultured in RPMI. All cell lines were obtained as a kind gift from Dr. Joe Gray, (Oregon Health Sciences University, USA), and maintained with 10% Fetal Bovine Serum (FBS) at 37 °C in 5% CO2 and 21% O2. All cell lines were verified by short tandem repeat (STR) genotyping. Genomic DNA was extracted by Wizard SV Genomic DNA purification system (Promega). STR profiles were compared with publically available profiles using Promega Powerplex 1.2.
Antibodies used in this report are as follows: ER-α (clone HC-20, Santa Cruz), HIF-1α (BD Bioscience), HIF-2α (NB100-132, Novus Biologicals), phospho-p70 S6 kinase (p-p70-S6K; 9205, Cell Signaling Technology), phospho-4E-BP1 (2855, Cell Signaling Technology), β-Actin (clone AC-15, Sigma-Aldrich), Alexa Fluor- 488 (A-11008, Invitrogen), Alexa Fluor-594 (A11012, Invitrogen), HRP-anti-Mouse IgG (NA931V, GE Healthcare), and HRP-anti-Rabbit IgG (NA934V, GE Healthcare). Reagents used in this study are estrogen (17-β-estradiol) used at 10 nM (Sigma-Aldrich), MG132 used at 10 uM (Cayman Chemical).
Western blots were performed as previously . Briefly, cells were lysed with urea lysis buffer (9 M urea, 150 mM, β-mercaptoethanol and 75 mM Tris pH 7.4), or RIPA buffer (Cell Signaling #9806), sonicated for 30 s and centrifuge at 15,00 rpm at 4C for 30 min. Protein quantification was performed by Bradford (BioRad Cat.500-0205), and 20–100 μg of protein were loaded in each well of a polyacrylamide gel. PVDF membranes were blocked with 5% milk in TBS-T/0.05% (Tris Buffered Saline with Tween 20 to 0.05%) at room temperature (RT) for 30 min, primary antibodies were incubated overnight at 4C in TBS-T/0.05%. After washing with TBS-T/0.05%, secondary incubation was performed at RT for 45 min followed by TBST/0.05% washes. Western blot signal was detected using Enhanced Chemiluminescent (ECL) substrate (Pierce 32106, or GE Healthcare RPN2235) in a FlourChemE machine. Exposures were chosen to provide maximum visual information about the changes in band intensity without causing overexposures that would obscure faint signals in neighboring lanes. Each western blot was repeated from 3 to 6 times, and the averages and standard deviations for the intensities of the western blot replicates for each figure are graphed and presented in tabular form in the Additional files, as indicated throughout the manuscript.
Cells were cultured on glass coverslips in six well plates, using complete media (RPMI or DMEM) with phenol red, supplemented with 10% FBS. Hypoxic samples were placed into the HypOxygen H35 Workstation for 48 h. Coverslips were washed twice in Phosphate Buffered Saline (PBS), fixed in Acetone 10 min at -20C, PBS washed, and nonspecific antibody binding blocked with 10% Bovine Serum Albumen (BSA) and 5% goat serum. Antibodies specific for the estrogen receptor alpha chain (Santa Cruz Biotechnology, HC-20 sc-543) were used at 1:100, anti- rabbit-488 (Molecular Probes/Invitrogen) at 1:1000. Nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole).
Plasmid transfection was performed using Lipofectamine (Invitrogen) and Plus Reagent (Invitrogen) in Opti-MEM. ShScramble, shHIF1A and shHIF2A plasmids were previously described , HIF-1αODD was used to produce stabilize HIF-1α at normoxia  pCMV-hER-α was used to overexpress ER-α . Reporter assays used ALT-4, a plasmid encoding canonical Estrogen Response DNA binding sequences (Estrogen Response Elements, ERE) controlling expression of firefly luciferase .
Cells were subjected to 1% O2 for the specified time (HypOxygen H35 Workstation). Cells were passaged under normoxic conditions but cultured and harvested inside the hypoxia chamber.
ER-α reporter assays and analysis of media estrogenic effects
To test the estrogenic effects of our normal culture media, cells were transfected with a plasmid encoding canonical Estrogen Response DNA binding sequences (Estrogen Response Elements, ERE) controlling expression of firefly luciferase . The media we tested included: 1) “standard growth media” containing phenol red, (DMEM for MCF7 or RPMI for BT474, T47D and ZR75B) with 10% FBS; or 2) “E2 (−), estradiol-free” composed of phenol red-free DMEM with 10% charcoal stripped FBS; or 3) “E2 (+), defined estrogen media”, composed of phenol red-free DMEM, 10% charcoal stripped FBS supplemented with 10 nM estradiol. Cells incubated with either standard growth media or cells grown in defined estrogen medium had similarly high levels of luciferase signal (Additional file 2). Since there was no difference between the standard media and the estrogen-defined, phenol red-free media, all experiments, ER-α transcriptional activity assays and proliferation assays were performed in standard media.
For experiments in Fig. 4, cells were transfected with a plasmid encoding canonical Estrogen Response DNA binding sequences (Estrogen Response Elements, ERE) controlling expression of firefly luciferase  and incubated at normoxia or at hypoxia for 48 h.
All luciferase activity was determined by Dual-Glo Luciferase assay reagent (Promega) measured in a Monolight 2010 Luminometer (Promega). Firefly luciferase was normalized to protein concentration.
In vitro growth curves
One hundred thousand cells were plated on 6-well plates in triplicate. The following day, cells were washed with PBS, and phenol red free DMEM with 10% charcoal stripped FBS was added. 10 nM estradiol was added for E2 (+) media or ethanol carrier for the E2 (−) media. Every 3 to 4 days, cells were counted.
Cell cycle analysis
Cells were plated into 6-well plates and cultured under appropriate conditions for 3 days (MCF7, T47D, ZR-75-B) or 6 days (BT474). Cells were harvested, fixed and permeabilized in suspension in 70% ethanol, nuclei were stained with 40 μg/ml propidium iodide and 100 μg/ml RNAse A. DNA content was analyzed using an Accuri C6 Fluorescence Activated Cell Sorter (BD Biosciences). At least 150,000 cells were analyzed per sample. Cell cycle fractions were determined using the cell cycle analysis component in the FLOWJO software package (FLOWJO Enterprise).
Real-time quantitative reverse transcriptase PCR
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. cDNA was generated from 1.5 μg of RNA using iScript (BioRad) following the manufacturer’s instruction. Power SYBR Green PCR reactions were performed in triplicate for each sample and analyzed using the AB Step One Plus sequence detection system. Data were normalized to TBP levels.
Student’s t-test was used to determine significance. All error bars represent the standard error of the mean. Two way ANOVA was performed for the growth curve experiments in Fig. 5 using the Graphpad Software package. Student’s t-test was also used to analyze whether our data would reveal enhanced proteolysis of the estrogen receptor alpha under hypoxic conditions reported in Fig. 3d and Additional file 3D . Although we may not have thoroughly inhibited proteolysis in these experiments, the MCF7 sample showed a statistically clear increase in protein stability with MG132 treatment in hypoxic conditions versus normoxic conditions, (significance level (alpha) = 0.05, p = 0.044), Additional file 3D. Data for the other three cell lines did not reach this significance, with p values for BT474 of 0.765, for T47D of 0.98, and for ZR-75-B of 0.69.
Hypoxia reduces ER-α protein levels
Estrogen or estrogenic surrogates such a phenol red (a common constituent of cell culture media) or various constituents of FBS, have been shown to simultaneously activate and induce degradation of ER-α (for example:  reviewed in ). Since our standard culture media contains phenol red and FBS and could therefore be considered to be constitutively activating ER-α, we tested whether the level of unoccupied ER-α would also be decreased under hypoxic conditions. We found that culture in the presence of charcoal-stripped serum and phenol red free media without added estradiol dramatically increased ER-α levels under normoxia in two representative cell lines in our collection (Fig. 1d, E2(−) N versus E2 (+) N lanes; Additional file 4C). However hypoxia still substantially reduced those ER-α levels in the absence of estrogen (E2(−) H versus (E2(−) N lanes).
HIF-1α activity reduces expression of ER-α
To directly investigate the role of HIF-1α in ER-α regulation, HIF1A was silenced by stably expressed shRNAs  in four genetically diverse ER-positive cell lines: MCF7, BT474, T47D and ZR75B. Knockdown was confirmed by qPCR (Fig. 2b, mRNA levels), and HIF-1α protein levels were determined by western blot (Fig. 2c; Additional file 7D; Additional file 9). HIF1A mRNA levels were reduced by about 50% in all cell lines. Silencing HIF1A in these lines partially prevented the hypoxic reduction in ER-α, implicating HIF-1α as a common mediator of ER-α modulation (Fig. 2c, H (hypoxic culture) lanes, shScramble versus shHIF1A). In contrast, HIF1A knockdown did not affect ER-α protein levels in normoxic conditions, since HIF-1α is not stable under normoxia (Fig. 2c, N (normoxic culture), lanes shScramble versus shHIF1A). In contrast, similar HIF2A knockdown experiments did not increase ER-α protein levels in either hypoxic or normoxic conditions (Additional file 7A, HIF2A mRNA; 7B, ER alpha protein; 7F western blot quantitation; Additional file 10). Finally, we tested whether overexpression of an oxygen-insensitive, stable HIF-1α allele (HIF-1αODD, ) would decrease ER-α levels in normoxic conditions, thereby isolating potential other effects of hypoxia from effects of HIF-1α. In transient transfection studies we found that stable HIF-1α can reduce ER-α protein levels (Fig. 2d; Additional file 7E; Additional file 11). Taken together, these findings indicate that HIF-1α reduces ER-α levels in response to hypoxia in breast cancer. Our results demonstrate that this is a general phenomenon, occurring in the context of different breast tumor genomes.
ER-α is post-transcriptionally regulated by hypoxia
ER-α levels might be decreased under hypoxic conditions if protein synthesis were inhibited, a phenomena which is reported to occur under anoxic conditions [39–41] and in non-transformed cells or weakly transformed cells under a variety of less severe O2 tensions . While this has not been attributed to HIF-1α activity, we tested whether protein synthesis was inhibited in our hypoxic cultures (1% O2), by testing for activating phosphorylation of two canonical regulators of protein synthesis: 4E-BP1 (a regulator of cap-dependent translation initiation), and p70 S6 Kinase (a regulator of polypeptide initiation and chain elongation). We found no decrease in activating phosphorylation of either of these proteins in hypoxic versus normoxic cultures (Fig. 3c N versus H; Additional file 3C; Additional file 12), indicating that global protein synthesis is not inhibited in our hypoxic cultures. In support of these findings, other reports indicate that in contrast to non-transformed cells, highly transformed breast tumor cell lines such as MCF7 and BT474 continue mRNA translation under hypoxic conditions similar to ours (1% O2 . Thus, we conclude that decreased translation of ESR1 mRNA is not the major cause of the reduced ER-α protein levels we observed.
We hypothesized that ER-α might be post-transcriptionally regulated. To test this, we treated four diverse ER-α -positive breast cancer cell lines (MCF7, BT474, T47D, and ZR75B) with the proteasome inhibitor MG132 (10 μM, 16 h). In each cell line, culture under hypoxic conditions with MG132 increased ER-α protein levels, despite their varying genetic backgrounds (Fig. 3d; Additional file 3D). We tested whether our experiments would reveal that this represented an increase in proteolysis under hypoxic versus normoxic conditions. Although we may not have inhibited proteolysis completely, we found that indeed MCF7 shows a statistically significant increase in ER-α protein levels by MG132 treatment in hypoxic conditions (alpha = 0.05, p = 0.044), Additional file 3D, Additional file 13. Data for the other three cell lines does not reach this significance, perhaps due to incomplete proteolysis inhibition.
We conclude that proteolysis plays a large role in the hypoxic regulation of ER-α. Analysis of mRNA levels in these experiments confirmed that increased levels of ER-α were not due to increased transcription of ESR1 with MG132 treatment (Additional file 3A). HIF-1α levels were also determined as a positive control for MG132 proteasome inhibitory activity (Fig. 3d; Additional file 3D; Additional file 14).
We further confirmed the posttranslational regulation of ER-α by overexpressing ER-α under the control of a strong hypoxia-insensitive promoter (cytomegalovirus; CMV; ) in the ER-negative cell line MDA-MB-231. We found that hypoxia (1% O2, 24 h) potently reduced ER-α protein levels in this line (Fig. 3b; Additional file 3B; Additional file 15). Furthermore, this experiment uniquely revealed that the mechanisms regulating ER-α protein abundance during hypoxia may not be limited to luminal, ER-α positive subtypes of breast cancer, but may be more widely activated by hypoxia in very disparate subtypes of breast tumors such as the claudin low, ER-α negative subtype represented by MDA-MB-231. We note that the increase in ER-α with MG132 treatment occurred although levels of HIF-1α were also increased. Taken together, these data suggest that proteasome activity is epistatic to HIF-1α in decreasing ER-α protein levels during hypoxia.
Hypoxia represses ER-α directed transcription
Hypoxia-induced decrease in of ER-α activity inhibits proliferation
The recent move towards precision medicine, which aims to prospectively identify clinical drug responders versus non-responders, requires a parallel preclinical move to the experimental use of panels of tumor-derived cell lines to more accurately assess possible therapeutic responses and frequencies. Here, we bridge that gap to define the effects of hypoxia on ER-α expression and activity in a panel of breast cancer cell lines that represent common genomic variations seen in human ER-α positive tumors. Previous work with exemplar cell lines, primarily MCF7 or ZR75, has suggested a role for hypoxia in reducing ER-α expression [28, 29, 31, 44]. However the literature taken as a whole contains multiple, conflicting results particularly with regard to mechanisms and with no consideration given to the potential influence of genetic background variations that commonly occur in ER-α positive tumors. Thus, common responses that might be relevant for improving hormonal therapies remain unclear.
We surprisingly find that reduced oxygen availability produces rapid reduction of ER-α protein levels in all of our genetically-diverse cell lines (Fig. 1a, b). This is largely effected by enhanced proteolysis, although a theoretical role for altered ER-α -specific translation attenuation cannot be entirely ruled out (Fig. 3d, Additional file 3D). Hypoxia reduces ER-α levels in essentially all of the cells within the population (Fig. 1c). We also uniquely find that the mechanisms that enhance proteolysis of ER-α during hypoxia can be activated even in breast tumor derivatives that are naturally ER-α negative and very distantly related, for example the claudin low molecular phenotype represented by MDA-MB-231 (Fig. 3b). Thus, we propose that the molecular mechanisms that promote ER-α proteolysis are likely to be fundamental to the hypoxic response, and that ER-α may be one of a potentially large suite of proteins that undergo proteolytic regulation during hypoxic adaptation. In support of this hypothesis, others have shown hypoxia-induced proteolysis of the α-secretases ADAM10 and TACE without alteration in mRNA levels in neuroblastoma , and of the MYC oncogene in human colon carcinoma cells and primary human keratinocytes, involving the ubiquitin ligases FBXW7 and DDB1, and cathepsins D and S . Similarly, the ubiquitin ligase Siah2 has been implicated in hypoxic proteolysis of the HIF-1α prolyl hydroxylases PHD1 and PHD3  and of the E1 subunit of α-ketogluterate dehydrogenase complex .
There is significant controversy regarding hypoxia-induced alterations in ESR1 mRNA levels. We find that none of the 10 cell lines in our panel show an obvious reduction in ESR1 mRNA abundance after 24 h of hypoxic culture, although they exhibit significant, rapid reduction in the level of ER-α protein (Fig. 1a versus Fig. 3a). This concurs with the findings in MCF7  and ZR75  which assessed mRNA at a similar time point (24 h). In other reports, a reduction in the level of ESR1 mRNA involving ERK kinase activity  were determined after 72 h of hypoxic culture, which may explain their discrepant results. Finally, reports of early (8–24 h), HIF-1α-dependent decreases in the levels of ESR1 mRNA  in MCF7 and T47D, contrast directly with our findings. These studies differed in that the level of ESR1 mRNA was analyzed in estrogen-starved cells in the presence versus absence of hypoxia. We predict that our results are most likely to represent the acute, common behavior of bona fide breast tumors undergoing hypoxic adaptation in an estrogenic environment such as the breast or metastatic site in the female body.
Using shRNAs targeting HIF1A and HIF2A we directly demonstrate that HIF-1α, but not HIF-2α commonly decreases ER-α protein levels (Fig. 2c versus Additional file 7B) in hypoxic culture conditions. However, these shRNA studies only decreased the levels of HIF-1α mRNA and protein without entirely eliminating expression, which may explain why ER-α protein levels were not more robustly restored in hypoxia in these cell lines (Fig. 2c). Similarly, transient overexpression of a stable HIF-1α in normoxic conditions did not entirely eliminate ER-α expression (Fig. 2d), which also might be explained as a technical failure to transfect all cells in the population. Alternatively, other hypoxia-induced factors that function independently of HIF-1α expression may also influence ER-α stability. For example, the weak HIF-2α expression seen under normoxic conditions might in fact be stabilizing ER-α in an unknown fashion, and the reduction in both molecules might be somehow linked in hypoxia. Proteases activated by hypoxia in other systems including cathepsins B, D, and S [46, 49] and calpains [50–52] as well as inducible E3 ubiquitin ligases such as SIAH2 [48, 53] may also provide HIF-1α - independent ER-α degradation in hypoxia. However it is clear from our studies that HIF-1α plays an important role in ER-α regulation.
Since mRNA levels of ESR1 do not decrease in response to hypoxia in any of the cell lines we examined (Fig. 3a), the decreased protein levels cannot result from direct transcriptional repression by HIF heterodimers or of HIF-induced transcriptional repressors. Thus HIF activity must indirectly influence factors that enhance proteolysis of ER-α. This may simply involve transcriptional induction of ubiquitin ligases or proteases, or more indirectly by induction of a known HIF-dependent transcriptional target such as miRNA-155 [54, 55] or a methyltransferase such as WDR5 . Alternatively, HIF-1α and ER-α might compete for transcriptional co-activators, for example P300/CBP (reviewed in ). In this scenario, increased hypoxic levels of HIF-1α could result in ER-α degradation, due to the lack of co-activators that prevent proteasome targeting. Finally, ER-α may compete with HIF-1α for VHL-mediated ubiquitination and proteasome targeting, as reported in renal cell carcinomas . Others have implicated HIF-1α in ER-α regulation by overexpression of chimeric HIF-1α-VP16  and by HIF-1α silencing by siRNA in a single cell line, MCF7 . However, our results demonstrate that this activity is more common among breast tumors than the results in MCF7 would suggest, and reveal that HIF-1α inhibitors should be further explored in preclinical studies as co-therapeutics in the endocrine therapy setting.
Finally, we find that the hypoxia-induced reduction in ER-α levels decreases ER-α -directed transcription (Fig. 4a-d) and significantly reduces proliferation (Fig. 5c-f) without inducing overt cell death in each cell line tested. Unexpectedly, this lack of estrogen signaling is not overcome by switching to other proliferative signaling pathways in any of our cells over the time courses we assessed (Fig. 5, 6–16 days). This leads us to speculate that chronic residence in hypoxic environments may be one explanation for the later disease reoccurrence seen in some ER-α positive breast cancer patients. We hypothesize that a dormant, non-proliferating phenotype may allow tumor cells to persist undetected, until conditions change to oxygenate the environment or until cells eventually switch to proliferation via other signaling pathways. We note that hypoxia can induce protein phosphatase 2A, which preserves viability without proliferation in glioblastoma multiforme-derived cells  and we speculate that a similar mechanism may be at play in our system. Furthers studies involving chronic hypoxia are ongoing in our laboratory. The hypoxia sensitivity of ER-α positive, but not ER-α negative, basal-like cell lines reported here may also provide one explanation for clinical observations that ER-α positive tumors grow more slowly than ER-α negative tumors, providing patients with better 5 year survival statistics. We speculate that ER-α negative tumors will grow in vivo regardless of environmental oxygen levels, whereas growth of ER-α positive tumors will be limited to that proportion of the tumor that is oxygenated. Finally, accounting for differential expression of ER-α and other hypoxia sensitive molecules in hypoxic regions of tumors offers one explanation for the intra-tumor heterogeneity of ER-α expression seen in many clinical breast tumor sections.
Several publications have shown that ER-α levels are reduced in regions of potentially hypoxic tissue in human clinical specimens, although in each case the authors were unable to determine whether this resulted from a lack of nutrients, oxygen, or an increase in cellular waste products. For example, Cooper et al.  examined cells adjacent to necrotic breast tumor cores by immuno-histochemical methods, and found that ER-α protein levels were decreased, HIF-1α levels increased, and expression of the HIF-1α target gene CA-IX was increased. Similarly, Kronblad et al.  also demonstrated reduced ER-α and increased HIF-1α halos of tumor cells surrounding necrotic cores. Finally Lloyd, et al.  measured the spatial distribution of ER-α reactivity in relationship to vascularity in breast tissue sections by immuno-histochemical staining. Each study found reduced ER-α levels either adjacent to necrotic cores or distal from vasculature. Unlike clinical results, we can definitely say that hypoxia alone is enough to produce reduced ERα protein levels in ER-α positive tumor cells despite variation in other accompanying genetic mutations.
This study is the first comprehensive overview of the effects of low environmental oxygen on ER-α abundance and transcriptional activity in a diverse set of culture adapted tumor cell lines independently derived from ER-α positive breast cancer patients. Our uniform, detailed analysis of this panel reveals surprising and potentially actionable homogeneity in the effect of hypoxia on ER-α. Our findings that there is a common requirement for the proteasome and HIF-1α in ER-α repression in hypoxic environments, among many different breast cancer genomes implies that ubiquitin ligase or proteasome inhibitors might be widely used in the clinic to potentiate the effects of hormonal therapies or delay/prevent therapeutic resistance. Similarly, the common requirement for HIF-1α activity implies that specific HIF inhibitors currently under development may also and perhaps more specifically improve current endocrine therapies. Thus this analysis reveals multiple new ideas for badly-needed improvements in endocrine-based therapeutics.
A disintegrin and metalloproteinase domain-containing protein 10
Aryl hydrocarbon receptor nuclear translocator
Coactivator binding protein
DNA damage-binding protein 1
Dulbecco’s modified Eagle’s media
Estrogen Response Element
Extracellular signal-regulated kinase
Estrogen receptor alpha
- ESR1 :
Estrogen receptor 1 gene
Fetal bovine serum
F-box and WD repeat domain containing 7
Human epidermal growth factor receptor 2
Hypoxia induced factor
Hypoxia induced factor 1 alpha
Hypoxia induced factor 1 beta
Avian myelocytomatosis viral oncogene homolog
- O2 :
Phosphate buffered saline
Phosphoinositide-3-kinase alpha catalytic subunit
Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform
Roswell Park Memorial Institute media
Short hairpin ribonucleic acid
Seven in absentia homolog 2
A disintegrin and metalloproteinase domain-containing protein 17
Tumor protein 53
Herpes simplex virus, viral protein 16
WD repeat domain 5
The authors thank Dr. Joe Gray for the panel of breast cancer cell lines and Dr David Shapiro (University of Illinois) for the ER-α and ER-luciferase reporter plasmids. We also thank Ricardo A. Mejia and Gloria E. Reynolds for technical assistance and Drs. Amato J. Giaccia, John P Murnane, Ester M. Hammond, Christine Janson, Lara Cobler, and Trent A. Watkins for helpful discussions.
This investigation was supported by startup funds provided to D.A.C. from the Department of Radiation Oncology, the V Foundation. A.J.K., NIH P20 GM104936 and NIH CA125618; L.A.T. NIH/NCI Bay Area Breast Cancer SPORE P50 CA58027. None of the funding sources had any role in the study design, data collection/analysis, interpretation of data, or writing of the manuscript.
Availability of data and material
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. All other data generated or analyzed during this study are included in this published article [and the Additional files].
MP made substantial contributions to the conception, design, data acquisition, and analysis of all data presented and is a major contributor to the manuscript production and editing. RJL provided substantial contribution to the conception, design and analysis of the data presented. BVL provided substantial technical contribution to the production of data, particularly the growth curves in Fig. 5, and contributed to the analysis of all data. LAT provided substantial intellectual contribution to the conception, design, and analysis of the data, directly performed experiments reported in Fig. 1c, and Fig. 5g, and is a major contributor to the manuscript production and editing. AJK provided substantial intellectual input regarding ER positive breast cancer, hypoxia and interpretation of experimental results. DAC PI, originator of the project, conceived, designed, and interpreted all experiments, wrote original manuscript drafts. All authors provided critical reviews of early manuscript drafts, have given final approval of the version to be published, and agree to be accountable for all aspects of the work, in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.View ArticlePubMedGoogle Scholar
- Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.View ArticlePubMedPubMed CentralGoogle Scholar
- Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010;121(1):53–64.View ArticlePubMedGoogle Scholar
- Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805–11.View ArticlePubMedGoogle Scholar
- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012;109(8):2724–9.View ArticlePubMedGoogle Scholar
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–22.PubMedPubMed CentralGoogle Scholar
- Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–34.View ArticlePubMedGoogle Scholar
- Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol. 2010;7(3):139–47.View ArticlePubMedGoogle Scholar
- Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12(1):9–22.PubMedPubMed CentralGoogle Scholar
- Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379(6560):88–91.View ArticlePubMedGoogle Scholar
- Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222–6.View ArticlePubMedGoogle Scholar
- Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res. 2005;569(1–2):75–85.View ArticlePubMedGoogle Scholar
- Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, Huang LE. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell. 2005;17(6):793–803.View ArticlePubMedGoogle Scholar
- Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol. 2000;17(5):869–79.PubMedGoogle Scholar
- Chaudary N, Hill RP. Hypoxia and metastasis in breast cancer. Breast Dis. 2006;26:55–64.View ArticlePubMedGoogle Scholar
- Harada H. How can we overcome tumor hypoxia in radiation therapy? J Radiat Res. 2011;52(5):545–56.View ArticlePubMedGoogle Scholar
- Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol. 2006;26(10):3955–65.View ArticlePubMedPubMed CentralGoogle Scholar
- Spriggs KA, Bushell M, Willis AE. Translational regulation of gene expression during conditions of cell stress. Mol Cell. 2010;40(2):228–37.View ArticlePubMedGoogle Scholar
- Chan DA, Sutphin PD, Yen SE, Giaccia AJ. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol. 2005;25(15):6415–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem. 2002;277(42):40112–17.View ArticlePubMedGoogle Scholar
- Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med. 2007;85(12):1301–7.View ArticlePubMedGoogle Scholar
- Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9 Suppl 5:10–7.View ArticlePubMedGoogle Scholar
- Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol. 2006;76:217–57.View ArticlePubMedGoogle Scholar
- Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006;12(15):4562–8.View ArticlePubMedGoogle Scholar
- Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res. 2004;10(24):8720–7.View ArticlePubMedGoogle Scholar
- Kronblad A, Hedenfalk I, Nilsson E, Pahlman S, Landberg G. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene. 2005;24(45):6835–41.View ArticlePubMedGoogle Scholar
- Ryu K, Park C, Lee Y. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. Biochem Biophys Res Commun. 2011;407(4):831–6.View ArticlePubMedGoogle Scholar
- Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol. 2002;16(10):2231–42.View ArticlePubMedGoogle Scholar
- Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529–41.View ArticlePubMedGoogle Scholar
- Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 2009;15(6):527–38.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang CC, Krieg S, Shapiro DJ. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol Endocrinol. 1999;13(4):632–43.View ArticlePubMedGoogle Scholar
- Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci U S A. 1999;96(5):1858–62.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer. 2014;14(1):26–38.View ArticlePubMedGoogle Scholar
- Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007;67(2):563–72.View ArticlePubMedGoogle Scholar
- Kaper F, Dornhoefer N, Giaccia AJ. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 2006;66(3):1561–9.View ArticlePubMedGoogle Scholar
- van den Beucken T, Magagnin MG, Jutten B, Seigneuric R, Lambin P, Koritzinsky M, Wouters BG. Translational control is a major contributor to hypoxia induced gene expression. Radiother Oncol. 2011;99(3):379–84.View ArticlePubMedGoogle Scholar
- Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem. 2008;283(24):16309–19.View ArticlePubMedPubMed CentralGoogle Scholar
- Cho J, Bahn JJ, Park M, Ahn W, Lee YJ. Hypoxic activation of unoccupied estrogen-receptor-alpha is mediated by hypoxia-inducible factor-1 alpha. J Steroid Biochem Mol Biol. 2006;100(1–3):18–23.View ArticlePubMedGoogle Scholar
- Yi JM, Kwon HY, Cho JY, Lee YJ. Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner. Biochem Biophys Res Commun. 2009;378(4):842–6.View ArticlePubMedGoogle Scholar
- Cho J, Kim D, Lee S, Lee Y. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol. 2005;19(5):1191–9.View ArticlePubMedGoogle Scholar
- Marshall AJ, Rattray M, Vaughan PF. Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels. Brain Res. 2006;1099(1):18–24.View ArticlePubMedGoogle Scholar
- Wong WJ, Qiu B, Nakazawa MS, Qing G, Simon MC. MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Mol Cell Biol. 2013;33(17):3494–504.View ArticlePubMedPubMed CentralGoogle Scholar
- Nakayama K, Qi J, Ronai Z. The ubiquitin ligase Siah2 and the hypoxia response. Mol Cancer Res. 2009;7(4):443–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014;19(2):285–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Wickramasinghe NS, Banerjee K, Nagaraj NS, Vigneswaran N, Zacharias W. Hypoxia alters cathepsin B / inhibitor profiles in oral carcinoma cell lines. Anticancer Res. 2005;25(4):2841–9.PubMedGoogle Scholar
- Rami A, Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 1993;609(1–2):67–70.View ArticlePubMedGoogle Scholar
- Azuma M, Hammond KB, Nakajima E, Shearer TR. Calpain protease causes hypoxia-induced proteolysis in cultured human retina. Curr Eye Res. 2014;39(4):421–4.View ArticlePubMedGoogle Scholar
- Kim MJ, Oh SJ, Park SH, Kang HJ, Won MH, Kang TC, Hwang IK, Park JB, Kim JI, Kim J, et al. Hypoxia-induced cell death of HepG2 cells involves a necrotic cell death mediated by calpain. Apoptosis. 2007;12(4):707–18.View ArticlePubMedGoogle Scholar
- Ma B, Chen Y, Chen L, Cheng H, Mu C, Li J, Gao R, Zhou C, Cao L, Liu J, et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat Cell Biol. 2015;17(1):95–103.View ArticlePubMedGoogle Scholar
- Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33(6):679–89.View ArticlePubMedGoogle Scholar
- Shen G, Li X, Jia YF, Piazza GA, Xi Y. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin. 2013;34(3):336–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, Teng SC, Wu KJ. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell. 2011;43(5):811–22.View ArticlePubMedGoogle Scholar
- Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ. Estrogen receptor alpha is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Cell Cycle. 2012;11(23):4462–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Hofstetter CP, Burkhardt JK, Shin BJ, Gursel DB, Mubita L, Gorrepati R, Brennan C, Holland EC, Boockvar JA. Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One. 2012;7(1), e30059.View ArticlePubMedPubMed CentralGoogle Scholar
- Lloyd MC, Alfarouk KO, Verduzco D, Bui MM, Gillies RJ, Ibrahim ME, Brown JS, Gatenby RA. Vascular measurements correlate with estrogen receptor status. BMC Cancer. 2014;14:279.View ArticlePubMedPubMed CentralGoogle Scholar